To this end, three EZH2 inhibitors (GSK-343, EPZ005687 and DZNeP) were investigated for their inhibitory effects on EZH2 levels in HPV-positive and HPV-negative HNSCC cell lines. Here, EZH2 is linked to head and neck squamous cell carcinoma.